Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Advanced Solid Tumors (CheckMate 032)
NCT01928394Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2013
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of nivolumab in triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PDAC), small cell lung cancer (SCLC), bladder cancer, sponsored by Bristol Myers Squibb. Started Oct 2013; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)pancreatic adenocarcinoma (PDAC)small cell lung cancer (SCLC)bladder cancer
Beyond the preview
Go deeper on NCT01928394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928394.